clonoSEQ (CLL, Blood/BM)
Chronic Lymphocytic Leukemia
FDA-ClearedCommercial
Key Facts
Indication
Chronic Lymphocytic Leukemia
Phase
FDA-Cleared
Status
Commercial
Company
About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage company on a mission to harness the adaptive immune system as a natural diagnostic and therapeutic tool. Its core achievement is the development of the Immune Medicine Platform, which sequences and maps immune receptors at scale, enabling both its growing clonoSEQ MRD diagnostics business and a deep drug discovery pipeline. The company's strategy is to leverage its unique, data-generating platform to create a sustainable competitive moat across both diagnostics and therapeutics, aiming to transform the detection, monitoring, and treatment of disease.
View full company profileOther Chronic Lymphocytic Leukemia Drugs
| Drug | Company | Phase |
|---|---|---|
| Dual Force Immunotherapy for CLL | ViferaXS | Phase 2 |